SCHEMBL115719

SCHEMBL115719

COc1cnccc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 12/20 0.53
ALDH1A1 P00352 4/20 0.53
KDM6B O15054 4/20 0.53
KDM4E B2RXH2 3/20 0.53
MAPT P10636 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
KDM4D Q6B0I6 2/20 0.53
MEN1 O00255 1/20 0.53
KDM4A O75164 1/20 0.53
THRB P10828 1/20 0.53
KMT2A Q03164 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HTT P42858 1/20 0.49
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30578227 1.00 KDM4C (0.53) KDM4CALDH1A1KDM6BKDM4EMAPT
Hydrochloric Acid SCHEMBL459608 0.98 KDM4C (0.52) KDM4CALDH1A1KDM6BKDM4EMAPT
Alcohol SCHEMBL28974265 0.93 KDM4C (0.49) KDM4CALDH1A1KDM6BKDM4EMAPT
SCHEMBL668446 0.85 KDM4C (0.49) KDM4CALDH1A1KDM6BKDM4EMAPT
SCHEMBL30465506 0.85 KDM4C (0.49) KDM4CALDH1A1KDM6BKDM4EMAPT
SCHEMBL459318 0.85 KDM4E (0.47) KDM4CALDH1A1KDM4EMAPTL3MBTL1
SCHEMBL30017867 0.84 KDM4C (0.46) KDM4CALDH1A1KDM6BKDM4EMAPT
SCHEMBL22868033 0.83 PTGS1 (0.52) KDM4CALDH1A1KDM6BKDM4EMAPT
Hydrochloric Acid SCHEMBL11590758 0.83 KDM4C (0.47) KDM4CALDH1A1KDM6BKDM4EMAPT
SCHEMBL3464020 0.83 KDM4C (0.47) KDM4CALDH1A1KDM6BKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115850349-B Metal complex catalyst and application thereof in preparation of 1,2, 3-pentamethylindane 山东新和成药业有限公司 2023-05-05 CN claimed
CN-115850349-A Metal complex catalyst and application thereof in preparation of 1,2, 3-pentamethyl indane 山东新和成药业有限公司 2023-03-28 CN claimed
EP-2822931-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF Inception 2, Inc. (US) 2015-01-14 EP claimed
WO-2013134562-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2013-09-12 WO claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4126835-B1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12516038-B2 Inhibitors of antigen presentation by HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-01-06 US disclosed
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 EP disclosed
WO-2024073475-A9 CEREBLON LIGANDS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) 2025-04-24 WO disclosed
CN-114341127-B Aminopyrazine compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2024-12-17 CN disclosed
CN-119110800-A Modulators of interferon gene stimulating factor (STING), compositions and methods 健道生物医药有限公司 2024-12-10 CN disclosed
US-20110039843-A1 HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-17 US disclosed
US-20110039843-A1 HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-17 US disclosed
US-20110039843-A1 HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-17 US disclosed
EP-2274983-A1 HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-01-19 EP disclosed
EP-2274983-A1 HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-01-19 EP disclosed
WO-2010125985-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-04 WO disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH KDM4C 3490/4885ALDH1A1 587/4885KDM6B 3795/4885
US-20110039843-A1 HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND C5, C9, C1S KDM4C 2742/4885ALDH1A1 883/4885KDM6B 3924/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 KDM4C 2269/4885ALDH1A1 1380/4885KDM6B 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.